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Reply
Thank you for your referral to our paper. Classifying athero-
sclerotic risk factors as conventional, predisposing, conditional,
and emerging represents current evidence on the relation, direct or
indirect, of the risk factor to atherosclerosis.
Regarding triglycerides, though clearly associatedwith cardiovas-
cular disease (CVD), whether they are causally related to atheroscle-
rosis and the exactmechanisms bywhich triglyceride-rich lipoproteins
exert their noxious effect on the vascular wall are matters of debate.
Primarily, it is still unclear whether it is the number of triglyceride-rich
lipoprotein particles or triglyceride-rich lipoprotein cholesterol or the
associated small dense low-density lipoprotein (LDL) and low
high-density lipoprotein(HDL) which contribute most to athero-
sclerosis. Secondarily, abnormal triglyceride concentrations often
accompany conditions, such as diabetes mellitus type 2 and the
metabolic syndrome, directly associated with increased CVD risk.1
When, however, solitary severe hypertriglyceridemia exists (eg, in
patients with familial lipoprotein lipase (LPL) or apolipoprotein
C-II deficiency, without diabetes or other CVD risk factors),
premature atherosclerosis is not usually seen.2
It should also be noted that in neither the Helsinki Heart
Study3 (4081 middle-aged men with elevated non-HDL-C ran-
domly received gemfibrozil 600 mg twice a day or placebo) nor
Veterans Affairs High Density Lipoprotein Cholesterol Interven-
tion Trial (VA-HIT)4,5 (2531 men with low HDL-C levels and
coronary heart disease (CHD) randomly received gemfibrozil
1200 mg/d or placebo) could any benefit be attributed to the
lowering of triglycerides, despite that both found a substantial reduc-
tion in CHD risk in association with gemfibrozil. In the Helsinki
Heart Study, benefit was associated with reduction of LDL-C levels
and an increase in HDL-C levels, whereas in VA-HIT, benefit was
associated with an increase in HDL-C levels and alteration of HDL
particles, as well as a decrease in inflammatory markers.
American College of Cardiology/AmericanHeart Association
(AHA/ACC) Guidelines suggest that if triglycerides are 500
mg/dl, the treatment of LDL-C to goal becomes a secondary
target.6 In this setting only, it is sensible to prioritize triglyceride-
lowering therapy, but not to primary prevent atherosclerosis, but
mainly to reduce the risk of pancreatitis. The recommendation is of
level C evidence.
Hypertriglyceridemia has not yet been established as a direct
causative factor of atherogenesis. Current evidence cannot support
classification of hypertriglyceridemia among conventional risk fac-
tors. We agree, however, that, it is an important vascular risk factor
associated to CVD and should not be neglected in the overall
management of the vascular patient.
Christos D. Liapis, MD
Efthimias D. Avgerinos, MD
Nicholas P. Kadoglou, MD
John D. Kakisis, MD
Department of Vascular Surgery
Attikon University Hospital
Athens, Greece
REFERENCES
1. Stalenhoef AFH, Graaf J. Association of fasting and non fasting serum
triglycerides with cardiovascular disease and the role of remnant-like
lipoproteins and small dense LDL. Curr Opin Lipidol 2008;19:355-61.2. Stalenhoef AF, Casparie AF, Demacker PN, Stouten JT, Lutterman JA,
van’t Laar A. Combined deficiency of apolipoprotein C-II and lipopro-
tein lipase in familial hyperchylomicronemia. Metabolism 1981;30:
919-26.
3. Frick MH, EIo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al.
Helsinki Heart Study: Primary prevention trial with gemfibrozil in
middle-aged men with dyslipidemia. Safety of treatment, changes in risk
factors, and incidence of coronary heart disease. N Engl JMed 1987;317:
1237-45.
4. RubinsHB, Robins SJ, Collins D, Fye CL, Anderson JW, ElamMB, et al,
for the Veterans Affairs High-Density Lipoprotein Cholesterol Interven-
tion Trial Study Group. Gemfibrozil for the secondary prevention of
coronary heart disease in men with low levels of high-density lipoprotein
cholesterol. N Engl J Med 1999;341:410-8.
5. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ,
McNamara JR, et al. Low-density lipoprotein and high-density lipopro-
tein particle subclasses predict coronary events and are favorably changed
by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein
Intervention Trial. Circulation 2006;113:1556-63.
6. Smith SC Jr, Allen J, Blair SN, BonowRO, Brass LM, FonarowGC, et al;
AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC
guidelines for secondary prevention for patients with coronary and other
atherosclerotic vascular disease: 2006 update: endorsed by the National
Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
doi:10.1016/j.jvs.2009.05.015
Regarding “Silent embolic infarcts on computed
tomography brain scans and risk of ipsilateral
hemispheric events in patients with asymptomatic
internal carotid artery stenosis”
In their elegant study, Dr Kakkos et al. found an increased risk
of ipsilateral symptomatic ischemic events in patients who had an
asymptomatic but hemodynamically significant internal carotid
artery stenosis and a previous ipsilateral silent embolic infarct.1
This is of great interest because, if it indicates a causal link between
the carotid artery stenosis and both the silent infarct and the
subsequent symptomatic event, then there is room for preventive
interventions like carotid endarterectomy or carotid artery stent-
ing. However, the study findings could also be explained by the
fact that silent brain infarcts, including ipsilateral ones, are non-
specific risk factors for subsequent symptomatic ischemic events,
including ipsilateral ones.2 A few more analyses could help inter-
preting the results before an intervention study.
First, if the carotid artery stenosis causes at least some of the
ipsilateral silent embolic infarcts, we expect finding more embolic
infarcts on the ipsilateral side on baseline computed tomography
(CT) scan. However, Table II of the article shows that more
infarcts were actually seen in the contralateral hemisphere. As
noted by the authors, patients with previous symptomatic con-
tralateral ischemic events were not excluded from the study and
could explain this surprise finding. How then, are baseline infarcts
distributed between the ipsi- and contralateral brain hemispheres
when patients with previous contralateral symptoms are excluded
from the analysis?
Second, if the relation between ipsilateral silent embolic in-
farcts and subsequent ipsilateral strokes is non-specific, we expect
that contralateral silent embolic infarcts will predict subsequent
ipsilateral strokes as well and, conversely, that ipsilateral silent em-
bolic infarct will predict subsequent contralateral strokes. What
then, is the ipsilateral stroke-free rate in patients with and without
a previous contralateral silent embolic infarct, and the contralateral
stroke-free rate in patients with and without a previous ipsilateral
silent embolic infarct?
Third, the authors provide stroke free survival rates in
patients with a previous ipsilateral embolic infarct and 60% to
99% stenosis or 60% to 79% stenosis. In both groups, there was
a striking difference compared with patients without previous
